-+ 0.00%
-+ 0.00%
-+ 0.00%

Hunter Capital RTO 1 posts Q2 operating loss of SEK 53,000; net sales at no revenue

PUBT·08/31/2026 07:12:34
Listen to the news
Hunter Capital RTO 1 posts Q2 operating loss of SEK 53,000; net sales at no revenue
  • Hunter Capital RTO 1 posted an EBITDA loss of SEK 53,000 for April–June 2026; net sales were nil.
  • Loss after financial items totaled SEK 53,000, translating to EPS of SEK -0.001.
  • Cash stood at SEK 510,000 at June 30, 2026; equity was SEK 534,000.
  • Work continued on the planned reverse acquisition of ResoTher Pharma, a Nordic clinical-stage biotech running a Phase 2a study.
  • The transaction remains subject to due diligence, regulatory approvals, financing, and shareholder decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hunter Capital RTO 1 AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 202608301801BITN____UKPR__SV_20260830-BIT-3992-0) on August 30, 2026, and is solely responsible for the information contained therein.